Can patients with benign breast disease who are at high risk for breast cancer be identified using bombesin estimation?

1994 ◽  
Vol 1 (2) ◽  
pp. 37-41
Author(s):  
A Milewicz ◽  
J Daroszewski ◽  
J Jedrzejak ◽  
W Bielanski ◽  
D Jedrzejuk ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Benign Breast Disease ◽  
Absolute Risk ◽  
Subsequent Development ◽  
Breast Disease ◽  
Cystic Disease ◽  
Tissue Concentrations ◽  
Increased Risk ◽  
Risk Of Cancer

ABSTRACT Clinical follow-up studies of women with breast cystic disease indicate an increased risk of subsequent development of breast cancer, but the absolute risk marker has not yet been identified. It has been shown that bombesin/gastrin-releasing peptide can stimulate the proliferation of breast cancer cells in culture. In order to address the question of whether biological measurements might identify women with benign breast disease (BBD) at particular risk for breast cancer, analyses of bombesin and dehydroepiandrosterone sulfate (DHEAS) levels in tumor tissue from patients with breast cancer and BBD were carried out. The groups of patients comprised 13 women with breast cancer (mean age 52.3 years), 12 women with fibroadenoma (mean age 47.5 years), 6 with microcystic breast disease (mean age 43.5 years) and 6 with gross cystic breast disease (mean age 47.2 years). Malignant and benign tumor tissues were collected after mastectomy or tumorectomy. Bombesin and DHEA-S levels was measured by RIA after homogenization and extraction of tissues. Bombesin concentrations were higher in women with breast cancer (83.67±21.07 ng/g) than in other groups, except women with gross cystic disease (79.6±10.9 ng/g). In contrast, tissue concentrations of DHEAS in women with breast cancer (130.5±34.5 μg/g) were lower with comparison to the others, except women with fibroadenoma (177.7±84.9 μg/g). Bombesin and DHEAS tissue concentrations showed significant negative correlation only in women with fibroadenoma. All values are means±S.D. The significantly higher bombesin levels in tissues from women with breast cancer and in breast benign gross cystic disease (high risk of cancer) suggests the possible role of bombesin in the malignant process. Further studies are necessary to confirm these initial results.

Characterizing benign breast disease in women at high risk for breast cancer.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 1506-1506
Author(s):  
S. A. Israel ◽  
H. Nassar ◽  
A. L. Gross ◽  
L. K. Jacobs ◽  
D. K. Armstrong ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Benign Breast Disease ◽  
Breast Disease

scholarly journals Effects of Tamoxifen on Benign Breast Disease in Women at High Risk for Breast Cancer

2003 ◽  
Vol 95 (4) ◽  
pp. 302-307 ◽  
Author(s):  
E. Tan-Chiu ◽  
J. Wang ◽  
J. P. Costantino ◽  
S. Paik ◽  
C. Butch ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Benign Breast Disease ◽  
Breast Disease

Benign Breast Diseases and Body Mass Index: Is There a Correlation?

2014 ◽  
Vol 80 (5) ◽  
pp. 461-465 ◽  
Author(s):  
Stacey O'Brien ◽  
Gopal Chandru Kowdley
Keyword(s):  
Breast Cancer ◽  
Body Mass Index ◽  
Body Mass ◽  
Breast Biopsy ◽  
Statistical Significance ◽  
Breast Disease ◽  
Breast Diseases ◽  
Increased Risk ◽  
Relationship Of ◽  
Risk Of Cancer

Breast cancer is the leading cancer affecting women in America. Body mass index (BMI) is a known risk factor for the development of breast cancer. The relationship of BMI to benign breast disease is less clear. In addition, certain benign pathologies are associated with an increased risk of cancer. We sought to measure the incidence of benign pathologies and to correlate these findings with BMI and age. All patients undergoing breast biopsy at our center from 2000 to 2005 were identified (n = 1717). Age, BMI, family history, sex, and diagnosis were determined. Patients were grouped into BMI, age, and intervention groups. χ2 ( P < 0.05) was used to identify statistical significance. Fibrocystic disease and fibroadenoma were seen with a lower incidence for patients older than 55 years of age, whereas pathologies requiring further surgical intervention were seen in higher proportions in patients older than 55 years of age. All pathologies were noted to decrease with increasing BMI, except for fibroadenoma, which peaked in BMI group 25 to 29.9 kg/m2. The presence of benign pathologies was associated with age as expected. Interestingly, although BMI is associated with increased risk of breast cancer, increasing BMI was not associated with benign pathologies that are associated with increased risk of breast cancer. Further study of this area is warranted.

Association of breast cancer and diabetes mellitus in Korean postmenopausal women

2020 ◽  
Author(s):  
Boram Kim ◽  
Jee Hye Han ◽  
Hee Yong Kwak ◽  
Kil Young Kwon ◽  
Junghwan Kim
Keyword(s):  
Breast Cancer ◽  
Diabetes Mellitus ◽  
Postmenopausal Women ◽  
Benign Breast Disease ◽  
Breast Disease ◽  
University Hospital ◽  
Control Group ◽  
Breast Clinic ◽  
Cancer Group ◽  
Increased Risk

Abstract Background: Diabetes mellitus has been associated with an increased risk of breast cancer. This association is, however, controversial, and not elucidated in Asia. This study aimed to determine the association between diabetes mellitus and breast cancer risk in Korean women.Methods: This retrospective study included subjects who underwent an ultrasound-localized needle-extracted biopsy to investigate questionable breast findings at the Eulji University Hospital breast clinic in Seoul, Korea, between 2000 and 2019. The medical records of the participants were reviewed to determine their age, diabetic status, and breast pathology findings. The participants were categorized into two groups, namely, the control group, that included those with benign breast disease; and, the breast cancer group. Logistic regression analyses were performed to assess the association between diabetes and breast cancer amongst pre- and post-menopausal participants.Results: A total of 1268 participants were included in this analysis. We found that diabetes was significantly associated with an increased odds of breast cancer (odds ratio [OR] 2.24; 95% confidence interval [CI], 1.76 to 2.84). Additionally, postmenopausal participants (aged ≥ 50 years) showed increased odds for breast cancer (OR 4.32; 95% CI, 3.37 to 5.53). The association between diabetes and breast cancer was significant, after adjusting for age, in the postmenopausal group (adjusted OR [aOR] 1.60; 95% CI, 1.09 to 2.35), but was not significant in the premenopausal group (aOR 1.10; 95% CI, 0.76 to 1.60).Conclusion: Diabetes was associated with increased odds of breast cancer compared to benign breast disease in postmenopausal women in Korea.

scholarly journals Macrophagic “Crown-like Structures” Are Associated with an Increased Risk of Breast Cancer in Benign Breast Disease

2017 ◽  
Vol 11 (2) ◽  
pp. 113-119 ◽  
Author(s):  
Jodi M. Carter ◽  
Tanya L. Hoskin ◽  
M. Alvaro Pena ◽  
Rushin Brahmbhatt ◽  
Stacey J. Winham ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Benign Breast Disease ◽  
Breast Disease ◽  
Increased Risk

scholarly journals A Cohort Study of p53 Mutations and Protein Accumulation in Benign Breast Tissue and Subsequent Breast Cancer Risk

2011 ◽  
Vol 2011 ◽  
pp. 1-9 ◽  
Author(s):  
Geoffrey C. Kabat ◽  
Rita A. Kandel ◽  
Andrew G. Glass ◽  
Joan G. Jones ◽  
Neal Olson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Confidence Intervals ◽  
Breast Tissue ◽  
Benign Breast Disease ◽  
P53 Protein ◽  
Breast Disease ◽  
Genetic Alterations ◽  
Protein Accumulation ◽  
Missense Mutations ◽  
Increased Risk

Mutations in the p53 tumor suppressor gene and accumulation of its protein in breast tissue are thought to play a role in breast carcinogenesis. However, few studies have prospectively investigated the association of p53 immunopositivity and/or p53 alterations in women with benign breast disease in relation to the subsequent risk of invasive breast cancer. We carried out a case-control study nested within a large cohort of women biopsied for benign breast disease in order to address this question. After exclusions, 491 breast cancer cases and 471 controls were available for analysis. Unconditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (95% CI). Neither p53 immunopositivity nor genetic alterations in p53 (either missense mutations or polymorphisms) was associated with altered risk of subsequent breast cancer. However, the combination of both p53 immunopositivity and any p53 nucleotide change was associated with an approximate 5-fold nonsignificant increase in risk (adjusted OR 4.79, 95% CI 0.28–82.31) but the confidence intervals were extremely wide. Our findings raise the possibility that the combination of p53 protein accumulation and the presence of genetic alterations may identify a group at increased risk of breast cancer.

HER-2/neu Amplification in Benign Breast Disease and the Risk of Subsequent Breast Cancer

2000 ◽  
Vol 18 (2) ◽  
pp. 267-267 ◽  
Author(s):  
Azadeh Stark ◽  
Barbara S. Hulka ◽  
Scott Joens ◽  
Debra Novotny ◽  
Ann D. Thor ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Amplification ◽  
Benign Breast Disease ◽  
Statistical Significance ◽  
Breast Disease ◽  
Case Group ◽  
Increased Risk ◽  
Histopathologic Diagnosis ◽  
Ductal Hyperplasia ◽  
Her 2

PURPOSE: The purpose of this study was to determine whether the presence of HER-2/neu gene amplification and/or overexpression in benign breast disease was associated with an increased risk of subsequent breast cancer. PATIENTS AND METHODS: We conducted a nested case-control study of a cohort of women who were diagnosed with benign breast disease at the Mayo Clinic and who were subsequently observed for the development of breast cancer. Patients who developed breast cancer formed the case group, and a matched sample from the remaining cohort served as controls. Benign tissue samples from 137 cases and 156 controls and malignant tissues from 99 cases provided DNA or tissue for evaluation of HER-2/neu amplification and protein overexpression. RESULTS: Among the controls, seven benign tissues (4.5%) demonstrated low-level HER-2/neu amplification, whereas 13 benign (9.5%) and 18 malignant (18%) tissue specimens from cases exhibited amplification. HER-2/neu amplification in benign breast biopsies was associated with an increased risk of breast cancer (odds ratio [OR] = 2.2; 95% confidence interval [CI], 0.9 to 5.8); this association approached statistical significance. The risks for breast cancer associated with benign breast histopathologic diagnoses were OR = 1.1 (95% CI, 0.6 to 1.9) for lesions exhibiting proliferation without atypia and OR = 1.5 (95% CI, 0.4 to 5.6) for the diagnosis of atypical ductal hyperplasia. For women having both HER-2/neu amplification and a proliferative histopathologic diagnosis (either typical or atypical), the risk of breast cancer was more than seven-fold (OR = 7.2; 95% CI, 0.9 to 60.8). Overexpression of the HER-2/neu protein product, defined as membrane staining in 10% or more of epithelial cells, was found in 30% of the breast tumors but was not detected in any of the benign breast tissues. Case patients who had HER-2/neu gene amplification in their malignant tumor were more likely to have had HER-2/neu amplification in their prior benign biopsy (P = .06, Fisher’s exact test). CONCLUSION: Women with benign breast biopsies demonstrating both HER-2/neu amplification and a proliferative histopathologic diagnosis may be at substantially increased risk for subsequent breast cancer.

scholarly journals Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer

2015 ◽  
Vol 33 (28) ◽  
pp. 3137-3143 ◽  
Author(s):  
Jeffrey A. Tice ◽  
Diana L. Miglioretti ◽  
Chin-Shang Li ◽  
Celine M. Vachon ◽  
Charlotte C. Gard ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Assessment ◽  
Primary Prevention ◽  
High Risk ◽  
Breast Density ◽  
Benign Breast Disease ◽  
Risk Model ◽  
Breast Biopsy ◽  
Breast Disease ◽  
History Of

Purpose Women with proliferative breast lesions are candidates for primary prevention, but few risk models incorporate benign findings to assess breast cancer risk. We incorporated benign breast disease (BBD) diagnoses into the Breast Cancer Surveillance Consortium (BCSC) risk model, the only breast cancer risk assessment tool that uses breast density. Methods We developed and validated a competing-risk model using 2000 to 2010 SEER data for breast cancer incidence and 2010 vital statistics to adjust for the competing risk of death. We used Cox proportional hazards regression to estimate the relative hazards for age, race/ethnicity, family history of breast cancer, history of breast biopsy, BBD diagnoses, and breast density in the BCSC. Results We included 1,135,977 women age 35 to 74 years undergoing mammography with no history of breast cancer; 17% of the women had a prior breast biopsy. During a mean follow-up of 6.9 years, 17,908 women were diagnosed with invasive breast cancer. The BCSC BBD model slightly overpredicted risk (expected-to-observed ratio, 1.04; 95% CI, 1.03 to 1.06) and had modest discriminatory accuracy (area under the receiver operator characteristic curve, 0.665). Among women with proliferative findings, adding BBD to the model increased the proportion of women with an estimated 5-year risk of 3% or higher from 9.3% to 27.8% (P < .001). Conclusion The BCSC BBD model accurately estimates women's risk for breast cancer using breast density and BBD diagnoses. Greater numbers of high-risk women eligible for primary prevention after BBD diagnosis are identified using the BCSC BBD model.

Sign in / Sign up

Export Citation Format

Share Document